Abstract

Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 1 prior therapy.

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in November 2012. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.